Key points
- The Invasive Staphylococcus aureus Infection Surveillance Program collects data for describing incidence and trends of these infections.
- Public health professionals and healthcare providers can use these data to further public health research and improve health outcomes.
Overview
As part of CDC's Emerging Infections Program (EIP) Healthcare-Associated Infections - Community Interface (HAIC) Activity, the Invasive Staphylococcus aureus (S. aureus) Infection Surveillance Program identifies and monitors:
- Changes in incidence of hospital-onset (HO), healthcare-associated community-onset (HACO), and community-associated (CA) invasive, methicillin-resistant and methicillin-sensitive S. aureus (MRSA and MSSA) infections.
- Populations with invasive S. aureus that would benefit from improved prevention and treatment activities.
- The impact of established prevention strategies.
- Molecular and microbiologic characteristics of strains causing invasive S. aureus infections.
To collect this information, trained professionals conduct active population- and laboratory-based surveillance in 7 EIP sites.
Public health professionals and healthcare administrators can use these data to further research and improve S. aureus prevention strategies.
Highlights
In 2020
HACO and CA MRSA incidence decreased, interrupting the previous increases since 2017.
HO MSSA incidence increased slightly and is the highest observed since 2017.
HACO and CA MSSA incidence decreased compared to 2018 and 2019.
Explore the data
Access and create data visualizations
Annual reports
- Invasive S. aureus, 2020
- Invasive S. aureus, 2019
- Invasive S. aureus, 2018
- Invasive S. aureus, 2017
- Invasive S. aureus, 2016
- Methicillin-Resistant S. aureus, 2015
- Methicillin-Resistant S. aureus, 2014
- Methicillin-Resistant S. aureus, 2013
- Methicillin-Resistant S. aureus, 2012
- Methicillin-Resistant S. aureus, 2011
- Methicillin-Resistant S. aureus, 2010
- Methicillin-Resistant S. aureus, 2009
- Methicillin-Resistant S. aureus, 2008
- Methicillin-Resistant S. aureus, 2007
- Methicillin-Resistant S. aureus, 2006
- Methicillin-Resistant S. aureus, 2005
Publications
- Rha B, See I, Dunham L, et al. Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections — United States, 2017–2020. MMWR Morb Mortal Wkly Rep 2023;72:153–159. DOI: http://dx.doi.org/10.15585/mmwr.mm7206e1.
- Jackson KA, Gokhale RH, Nadle J, et al. Public Health Importance of Invasive Methicillin-sensitive Staphylococcus aureus Infections: Surveillance in 8 US Counties, 2016. Clin Infect Dis. 2020;70(6):1021-1028. doi:10.1093/cid/ciz323
- See I, Mu Y, Albrecht V, et al. Trends in Incidence of Methicillin-resistant Staphylococcus aureus Bloodstream Infections Differ by Strain Type and Healthcare Exposure, United States, 2005-2013. Clin Infect Dis. 2020;70(1):19-25. doi:10.1093/cid/ciz158
- Grigg C, Palms D, Stone ND, et al. Burden of Invasive Methicillin-Resistant Staphylococcus aureus Infections in Nursing Home Residents. J Am Geriatr Soc. 2018;66(8):1581-1586.
- Jackson KA, Bohm MK, Brooks JT, et al. Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016. MMWR Morb Mortal Wkly Rep 2018;67:625–628. DOI: http://dx.doi.org/10.15585/mmwr.mm6722a2
About the data
Methods
EIP sites conducting surveillance
For Connecticut and Georgia, the MSSA surveillance area is a subset of the total MRSA surveillance area. In Connecticut, the MSSA surveillance area is the South Central Connecticut Planning Region. In Georgia, the MSSA surveillance area is Fulton County.
Case definition
When S. aureus is isolated from a normally sterile body site in a patient who lives in the surveillance area. Sterile body sites can include:
- Blood
- Cerebrospinal fluid (CSF)
- Pleural fluid
- Peritoneal fluid
- Pericardial fluid
- Bone
- Joint/synovial fluid
- Internal body site (e.g., lymph node, brain)
Data collection
The invasive S. aureus infection surveillance program is an active population- and laboratory-based surveillance system. Surveillance staff regularly query clinical laboratories to identify microbiological test results among persons living in a defined geographic area.
- Rose AN, Clogher P, Hatfield KM, Gokhale RH, See I, Petit S. Trends in methicillin-resistant Staphylococcus aureus bloodstream infections using statewide population-based surveillance and hospital discharge data, Connecticut, 2010-2018. Infect Control Hosp Epidemiol. 2020;41(6):734-736. doi:10.1017/ice.2020.72
- Jackson KA, Gokhale RH, Nadle J, Ray SM, Dumyati G, Schaffner W, Ham DC, Magill SS, Lynfield R, See I. Public health importance of invasive methicillin-sensitive Staphylococcus aureus infections: Surveillance in 8 US counties, 2016. Clin Infect Dis. 2020 Mar 3;70(6): 1021-1028. doi: 1093/cid/ciz323
- Hartnett KP, Jackson KA, Felsen C, McDonald R, Bardossy AC, Gokhale RH, Kracalik I, Lucas T, McGovern O, Van Beneden CA, Mendoza M, Bohm M, Brooks JT, Asher AK, Magill SS, Fiore A, Blog D, Dufort EM, See I, Dumyati G. Bacterial and fungal infections in persons who inject drugs – Western New York, 2017. Morbid Mortal Wkly Rep. 2019 July;68(26): 583-586.
- Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, Nadle J, Kainer MA, Dumyati G, Petit S, Ray SM, Emerging Infections Program MRSA author group, Ham D, Capers C, Ewing H, Coffin N, McDonald CL, Jernigan J, Cardo D. Vital Signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections – United States. Morbid Mortal Wkly Rep. 2019 Mar;68(9):214-219.
- See I, Mu Y, Albrecht V, Karlsson M, Dumyati G, Hardy DJ, Koeck M, Lynfield R, Nadle J, Ray SM, Schaffner W, Kallen AJ; Trends in incidence of methicillin-resistant Staphylococcus aureus bloodstream infections differ by strain type and healthcare exposure, United States, 2005–2013 . Clin Infect Dis. 2020 Jan 1:70(1):19-25, ciz158.